NASDAQ:STOK - Stoke Therapeutics Stock Price, Forecast & News

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Stoke Therapeutics (NASDAQ:STOK) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. View Stoke Therapeutics' Earnings History.

Stoke Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Stoke Therapeutics.

7 equities research analysts have issued 12-month price objectives for Stoke Therapeutics' shares. Their forecasts range from $30.00 to $46.00. On average, they expect Stoke Therapeutics' share price to reach $36.50 in the next year. This suggests a possible upside of 54.3% from the stock's current price. View Analyst Price Targets for Stoke Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stoke Therapeutics.

Headlines about STOK stock have trended extremely negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stoke Therapeutics earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Stoke Therapeutics.

Stoke Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,360,000 shares, an increase of 28.3% from the December 15th total of 1,060,000 shares. Based on an average daily volume of 136,400 shares, the short-interest ratio is presently 10.0 days. Currently, 8.8% of the shares of the company are short sold. View Stoke Therapeutics' Current Options Chain.

Some companies that are related to Stoke Therapeutics include Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Taro Pharmaceutical Industries (TARO), Myokardia (MYOK), Blueprint Medicines (BPMC), Zai Lab (ZLAB), Apellis Pharmaceuticals (APLS), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Axsome Therapeutics (AXSM), Emergent Biosolutions (EBS), Genmab A/S (GMAB), Alkermes (ALKS) and Biohaven Pharmaceutical (BHVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gilead Sciences (GILD), Horizon Therapeutics (HZNP), Exxon Mobil (XOM), Exelixis (EXEL), Infinera (INFN), OptiNose (OPTN), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO), BCE (BCE) and British American Tobacco (BTI).

(STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics' lock-up period expired on Monday, December 16th. Stoke Therapeutics had issued 7,891,110 shares in its initial public offering on June 19th. The total size of the offering was $142,039,980 based on an initial share price of $18.00. Since the end of Stoke Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STOK stock can currently be purchased for approximately $23.66.

Stoke Therapeutics has a market capitalization of $774.39 million. Stoke Therapeutics employs 44 workers across the globe.View Additional Information About Stoke Therapeutics.

The official website for Stoke Therapeutics is http://www.stoketherapeutics.com/.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]